Asinex has agreed a one year prolongation to its multi-FTE deal with Avalon Pharmaceuticals, a next-generation genomics-based company
Asinex will perform chemical lead optimisation for Avalon Pharmaceuticals, of compounds discovered through the use of diverse, small molecule collections from both companies, for another year.
To date, the medicinal chemistry departments at both Asinex and Avalon have been involved in the design and synthesis of compounds derived from initial hits of certain high throughput screening assays.
Several optimisation programmes have been completed, resulting in the delivery of potential drug candidates to Avalon.
Staszek Pikul, senior scientific director at Avalon stated, " We have been very pleased by the quality of work of Asinex chemists and by the contribution they made to a rapid progression of our lead optimisation programmes. "It's been a good and productive collaboration and I am happy to see Asinex and Avalon continue working together for another year".
Mikhail Kirpichenok, director of research at Asinex, commented, "We are delighted that Avalon has agreed to continue its collaboration with Asinex for another year. "This is validation of the work that we have performed during the last year, we hope that this alliance will continue for many more years."
